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Objective: To investigate the effect of radiotherapy plus recombinant human endostatin
(RH-endostatin) on esophageal cancer and its mechanism.
Methods: A total of 50 nudemice were equally randomized into control group, radio-
therapy group, and combined therapy group I, II, and III after inoculating with Eca109
cell suspension (1 × 107 cells/mL). On the day of grouping, control group and radio-
therapy group were injected normal saline, while radiotherapy group and 3 combined
therapy groups received radiotherapy; besides, combined therapy group I, II, and III was
injected RH-endostatin of 2.5, 5, 10 mg/kg respectively. After 3-week therapy, the tumors
of each group were collected and microvessel density and VEGF expression in tumors
were determined. In vitro, Eca109 cells were divided into control group, radiotherapy
group, and combined therapy group. Forty-eight hours after treatment, cell cycle distri-
bution and apoptosis rate were detected, and the activity of VEGF signal paths was
semiquantitatively analyzed.
Results: Since the 6th day of treatment, the relative tumor proliferation rate of com-
bined therapy group II was lower than radiotherapy group (P < 0.05) and 40% since
the 15th day. Average microvessel density and EGFR expression in combined therapy
group II were lower than radiotherapy group (P < 0.05). In vitro, the cell percentage in
S and G2/M phase of combined therapy group cells was lower than that in radiotherapy
group cells, while the apoptosis rate and the expression of VEGF, AKT, p-AKT,
ERK1/2 and p-ERK1/2 in combined group were higher than that in radiotherapy group
(P < 0.05).
Conclusions: RH-endostatin promotes the efﬁcacy of radiotherapy on esophageal can-
cer, which may be partly realized by inhibiting the activity of VEGF related signal paths.1. Introduction
Esophageal cancer is the most common malignant tumor in the
digestive system, with characteristics including high incidence,
strong invasion activity and poor prognosis [1]. Although operation
is still the standard therapy for local esophageal cancer, the cure
rates following surgery alone are poor with three-year and ﬁve-
year survival rates ranging from 6% to 35% [2,3].As research continues, people learn the important role of
tumor neovascularization in tumor growth and metastasis. In
1971, Folkman [4] proposed that the growth of tumor relied on
new vessels, because cancer cells stopped growing due to lack
of oxygen and nutrition when they were more than 2 mm
away from vessels. According to the theory of Angiogenic
Switch [5], the growth of tumor vessels is reached together by
a series of complicated mechanisms of the promoting factors
and inhibitors in which vascular endothelial growth factor
(VEGF), basic ﬁbroblast growth factor, epidermal growth
factor, and tumor necrosis factor a are included. Thereinto,
VEGF is the most speciﬁc and strongest promoting factor.
Studies showed that VEGF was highly expressed in
esophageal cancer, and its high expression was related to high
grade, poor prognosis and poor radiosensitivity and
chemosensitivity [6,7].C BY-NC-ND license (http://
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clinical studies through inhibiting neovascularization and
improving hypoxia, etc. Whether these drugs could enhance
the radiosensitivity in the combination therapy is a hotspot.
Recombinant human endostatin (RH-endostatin) is an anti-
angiogenesis drug without obvious cytotoxicity and toler-
ance. Moreover, it can also inhibit tumor angiogenesis in a
multi-target way [8,9]. In a clinical study on non-small cell lung
cancer (NSCLC), 486 NSCLC patients in progressive stage
were randomized into chemotherapy group and chemotherapy
plus RH-endostatin group (combined therapy group) and the
overall survival rate of two groups was respectively 19.5% and
35.4%, which indicated that the combined therapy could
signiﬁcantly improve the survival of NSCLC patients [10].
Itasaka studied the combined effect of RH-endostatin and
radiotherapy on cancer cell A431 and found that RH-
endostatin could prevent tumor vascular reconstruction in
mice legs after radiation, thus enhancing the efﬁcacy of
radiotherapy [11].
Currently, there are few reports on the effect of RH-
endostatin in esophageal cancer. In the study we established
xenograft model of esophageal cancer in nudemice and adopted
the combined therapy of radiotherapy and with RH-endostatin,
in order to validate the efﬁcacy of this combined therapy.
2. Materials and methods
2.1. Experimental animals and cell line
A total of 50 male Balb/c nudemice (aging 4–5 weeks and
weighing 18–20 g) were fed in separate cages in SPF laminar ﬂow
room. Human esophageal cancer cell line Eca109, were cultured in
the RPMI 1640 medium containing 10% fetal bovine serum. This
study was approved by the Ethics Committee of No.153 Hospital
of Liberation Army, and the procedures of the experiments were
complied with the Declaration of Helsinki.
2.2. Assays in vitro
Eca109 cells incubated in 6-well plate were adjusted to
logarithmic phase and divided into control group, radiotherapy
group, and combined therapy group, with 3 parallel wells for
each group. The radiotherapy group and combined therapy
group were both radiated by linear accelerator with dose of 2 Gy
at room temperature; before the radiation, the combined therapy
group cells additionally received the treatment of 20 mg/mL RH-
endostatin. After the radiation, all groups were further cultured
for 48 h, and then cells were harvested. The harvested cells were
made into single cell suspension and adjusted to 5 × 105 cells/
mL. After three times of washing by PBS, the cells were
resuspended in 200 mL Binding Buffer. Then, 10 mL Annexin V-Relative Tumor Proliferation Rate

T
C

=
Average RVT of Therapy Grou
Average RVT of Control GrouFITC and 10 mL propidium iodide solution were added and
mixed gently. After 15 min of incubation at room temperature in
dark, 300 mL Binding Buffer was added. One hour later, cell
apoptosis rate and cell cycle distribution were determined by
ﬂow cytometry.
Cells received the same treatment were harvested for
extracting the total protein by cell lysis kit. Then, a rabbit anti-
human VEGF monoclonal antibody, rabbit anti-human AKT
polyclonal antibody, rabbit anti-human ERK1/2 polyclonal
antibody were used as the primary antibody, respectively, and a
horseradish peroxidase-conjugated IgG antibody was used as the
secondary antibody for Western-blot analysis. b-actin was used
as a control. UVIDoc Imager was used for the gray value
analysis of protein band.
2.3. Establishment of xenograft model of esophageal
cancer in mice and grouping
Eca109 cells in logarithmic phase were made into cell sus-
pension at 1 × 107 cells/mL by 0.25% trypsin. Then, 0.2 mL cell
suspension was inoculated subcutaneously into right axilla of
nude mouse. When the transplanted tumor grew to 150–
250 mm3 (about one week after inoculation), nudemice were
divided into control group, radiotherapy group and combined
group I, II, and III (n = 10), in accordance with the random
number table.
From d 8 post-inoculation, the control group received normal
saline 0.1 mL/d through intraperitoneal injection; the radio-
therapy group received radiotherapy; the combined therapy
group I, II, and III received radiotherapy plus daily injection of
2.5 mg/kg, 5 mg/kg, and 10 mg/kg RH-endostatin respectively.
Radiation methods: After being anesthetized by 100 mg/kg ke-
tamine and 10 mg/kg xylazine, nudemice were ﬁxed and only
exposed their legs growing with transplanted tumor; radio-
therapy was conducted by medical linear accelerator, with
6 MV-X-ray, SSD 100 cm, a dose of 10 Gy for each time and a
dose rate 300 cGy/min. After 21-day treatment, mice were
sacriﬁced for collecting tumors.
2.4. Therapeutic evaluation
Before the ﬁrst dose and since then, the length (L) and width
(W) of transplanted tumor were measured every three days, the
volume of transplanted tumor was calculated (V = 1/2 L × W2),
and the relative tumor volume (RTV) of all the groups were
compared (RTV = volume after treatment/volume before treat-
ment). Relative tumor proliferation rate (T/C, %) was used to
reﬂect the effect of drug intervention. When T/C(%)  40% and
P < 0.05 after statistical processing, the therapy was considered
effective.p
p
× 100%
Table 2
Levels of MVD and VEGF protein in tumor tissues.
Groups MVD (mm2) VEGF protein
Control group 108.22 ± 16.22 0.43 ± 0.06
Radiotherapy group 73.95 ± 13.72a 0.38 ± 0.03
Combined therapy group I 60.14 ± 11.88a 0.34 ± 0.04a
Combined therapy group II 40.52 ± 9.06ab 0.23 ± 0.03ab
Combined therapy group III 54.98 ± 10.25a 0.30 ± 0.03a
Note: a vs. control group, p < 0.05; b vs. radiotherapy group, p < 0.05.
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Tumors specimen were made into tissue slices, passing
through ﬁxing, routine decoloring, embedding and slicing.
Immunohistochemical SABC staining was applied to CD34. The
average number of positive blood vessels in 3 hotspots was
recorded as MVD. The same method was conducted to detect
the expression of VEGF protein. Image-Pro Plus 6.0 software
was used to detect the absorbance value of the positive staining
region, with the average integral optical density representing the
content of VEGF.
2.6. Data statistics analysis
SPSSl8.0 software was used for statistical analysis and all the
data were represented by mean ± SD. All the experiments
in vitro were repeated three times. One-way ANOVA was
adopted to compare means among groups. When P < 0.05, the
difference was considered statistically signiﬁcant.
3. Results
3.1. Evaluation of xenograft model and therapeutic effect
One week after inoculation, the average volume of the
subcutaneous tumor nodules was 290 mm3, and the tumor
formation rate was 100%. There was no signiﬁcant difference
in body weight and tumor weight among groups before treat-
ment (P > 0.05) (Table 1). After beginning the therapy,
compared with control group, the tumor volume and the RTV
in radiotherapy group and 3 combined therapy groups
decreased signiﬁcantly (P < 0.05); in the 3 combined therapy
groups, only combined therapy group II was lower than
radiotherapy group in tumor volume and RTV (P < 0.05)
(Table 1).
At day 7 of treatment, the relative tumor proliferation rate (T/
C, %) of combined therapy group II was lower than radiotherapy
group (P < 0.05), and at day 21 of treatment, T/C of this groupTable 1
Tumor volume, RTV and relative tumor proliferation rate (T/C, %) of each
Before treatment
Tumor volume (mm3)
Control group 263.54 ± 10.94 521.9
Radiotherapy group 262.31 ± 12.16 442.2
Combined treatment group I 258.57 ± 12.32 397.2
Combined treatment group II 261.92 ± 10.74 360.6
Combined treatment group III 260.63 ± 12.16 368.1
Relative tumor volume (RTV)
Control group – 1.9
Radiotherapy group – 1.6
Combined treatment group I – 1.5
Combined treatment group II – 1.3
Combined treatment group III – 1.4
Relative tumor proliferation rate (T/C, %)
Radiotherapy group – 0.8
Combined treatment group I – 0.7
Combined treatment group II – 0.6
Combined treatment group III – 0.7
Note: a vs. control group, p < 0.05; b vs. radiotherapy group, p < 0.05.was less than 40% while the other groups was always more than
40% during treatment.
3.2. Analysis of MVD and expression of VEGF protein
Table 2 showed that after treatment, the average MVD and
VEGF expression of all therapy groups were lower than control
group; the average MVD and VEGF expression of combined
therapy group II were lower than radiotherapy group
(P < 0.05).
3.3. Cell cycle distribution and apoptosis rate
Results showed that the percentage of cells in S phase and
G2/M phase of combined therapy group signiﬁcantly decreased
and that in G0/G1 phase was obviously increased (P < 0.05),
compared with control group and radiotherapy group. The
apoptosis rate of two therapy groups were both higher than
control group and the combined group was higher than radio-
therapy group (P < 0.05) (Table 3).
In order to explore the mechanism of RH-endostatin inhib-
iting the neovascularization in which VEGF participated, we
detected the expression of VEGF and VEGF signal paths related
proteins (AKT, p-AKT, ERK1/2, and p-ERK1/2) in cell. Table 4
showed that the protein expressions of two therapy groups
decreased obviously compared with control group, and the
combined therapy group was lower than radiotherapy group
(P < 0.05).group at different time points before and after beginning the treatment.
Day 7 Day 14 Day 21
3 ± 14.52 797.81 ± 19.13 1049.24 ± 70.17
3 ± 16.64 530.02 ± 17.68a 621.78 ± 21.11a
8 ± 14.97a 476.77 ± 15.46a 532.18 ± 17.45a
5 ± 13.05ab 402.03 ± 13.85ab 429.82 ± 14.29ab
4 ± 13.79a 443.50 ± 14.23a 491.31 ± 15.94a
9 ± 0.29 3.03 ± 0.32 3.99 ± 0.37
9 ± 0.23 2.01 ± 0.24a 2.38 ± 0.27a
3 ± 0.20a 1.85 ± 0.21a 2.05 ± 0.23a
7 ± 0.18ab 1.52 ± 0.19ab 1.63 ± 0.21ab
1 ± 0.22a 1.70 ± 0.25a 1.88 ± 0.26a
6 ± 0.07 0.67 ± 0.06 0.60 ± 0.05
6 ± 0.07 0.60 ± 0.05 0.51 ± 0.04
7 ± 0.05b 0.49 ± 0.03b 0.40 ± 0.03b
1 ± 0.06 0.56 ± 0.04 0.46 ± 0.04
Table 4
Ratio of gray value of target protein/b-actin.
Groups VEGF AKT p-AKT ERK1/2 p-ERK1/2
Control cells 1.05 ± 0.23 0.65 ± 0.13 0.48 ± 0.08 0.88 ± 0.09 0.67 ± 0.05
Radiotherapy cells 0.82 ± 0.15a 0.50 ± 0.09a 0.33 ± 0.05 0.69 ± 0.12a 0.50 ± 0.06a
Combined therapy cells 0.45 ± 0.07 ab 0.29 ± 0.04 ab 0.20 ± 0.03 ab 0.33 ± 0.06 ab 0.28 ± 0.03 ab
Note: a vs. control group, P < 0.05; b vs. radiotherapy group, P < 0.05.
Table 3
Cell cycle distributions and apoptosis rate in each groups (%).
Groups G0/G1 phase S phase G2/M phase Apoptosis rate
Control cells 40.02 ± 1.25 36.31 ± 0.94 23.67 ± 0.78 6.32 ± 0.81
Radiotherapy
cells
46.22 ± 1.36 35.97 ± 1.03 17.81 ± 1.16a 10.41 ± 0.96a
Combined
therapy cells
71.45 ± 2.39ab 22.38 ± 0.89ab 6.17 ± 0.54ab 18.92 ± 1.44ab
Note: a vs. control group, p < 0.05; b vs. radiotherapy group, p < 0.05.
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Surgical excision is the main method to treat esophageal
cancer, which can cure patients at the early stage. Al-Herz found
that the 1-year survival rate and 5-year survival rate of esoph-
ageal cancer were respectively 78.3% and 30.3% [12].
Radiotherapy is considered as an effective local therapy not
requiring cutting off organs, which makes it an option for
patients unable or unwilling to be operated on. In contrast
with surgery, radiotherapy brings less pain, no hospitalized
mortality and severe complications.
At present, in China most conﬁrmed esophageal cancer pa-
tients are in mid and late stage, and radiotherapy is the main
option of therapy. It is difﬁcult to diagnose esophageal cancer in
early stage, only 20% of patients in mid or late stage are suitable
for surgery and about 80% of patients receiving operation also
need radiotherapy after resection.
In the study, radiotherapy plus RH-endostatin was used to
treat xenograft of esophageal cancer in nudemice, and the results
showed that radiotherapy plus 5 mg/kg/d RH-endostatin could
signiﬁcantly inhibit tumor proliferation. However, radiotherapy
plus 2.5 mg/kg or 10 mg/kg RH-endostatin did not display the
same anti-tumor effect. Celik et al. [13] used RH-endostatin to
intervene in transplanted pancreatic cancer, and found the optimal
dosage of intervention was 250 mg/kg/d, while less or more than
the dosage showed the less inhibition of tumor, which is similar
to our study. The treatment of anti-tumor angiogenesis drug
bevacizumab in colorectal cancer and the intervention of ATN-
161 in Lewis lung cancer also showed the same characteristic
[14,15]. Peyman et al. evaluated the effects of ascorbic acid on
experimentally induced corneal neovascularization in the rat
model, and in the 7 working concentrations from 250 mg/mL to
100 mg/mL, they found the optimal dose–effect relation was in
concentrations between 1 mg/mL and 500 mg/mL [16]. In the
study, when the dose of RH-endostatin was 5 mg/kg/d, there
was the best inhibition of tumor angiogenesis, which indicates
that this dosage was the most optimal working concentration.
In accordance with the above results, when radiotherapy plus
5 mg/kg/d RH-endostatin was given, MVD and VEGF expres-
sion in tumors both reached the lowest level. Meanwhile, in vitro,
the expression level of proteins related to VEGF signal pathways(AKT, p-AKT, ERK1/2, and p-ERK1/2) was the lowest when
cells received combined therapy. As the PI3K/AKT path and
PLC-g/PKC/ERK1/2 path are both related to angiogenesis [17,18],
angiogenesis would be weakened when the expression of VEGF
is inhibited. But now the mechanism of RH-endostatin is not yet
completely understood, it is unclear whether RH-endostatin will
inﬂuence tumor proliferation and angiogenesis through other
ways. For example, Xiao L et al. found treatment of RH-
endostatin could attenuate b-FGF-activated phosphorylation of
p38 and ERK1/2 in human umbilical vein endothelial cells which
indicate that endostatin might exert its anti-tumor effect via
suppressing b-FGF-induced angiogenesis and b-FGF-activated
MAPK signaling pathway [19]. Wan [20] even found that
endostatin had an epithelium-protective effect and inhibited the
inﬂammation in the pathogenesis of pulmonary ﬁbrosis.
In conclusion, radiotherapy plus RH-endostatin could
signiﬁcantly improve the efﬁcacy of radiotherapy for esophageal
cancer, which may be partly realized by inhibiting the VEGF
signal paths, and then inhibits tumor angiogenesis.
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